Jeff Barnes joined Oxford Bioscience Partners in 1999 where he is a General Parnter and has over 20 years of operating and investment experience in the life sciences sector. Prior to Oxford, he worked at the investment banking firms of Robertson, Stephens & Co. and Needham & Co. where he was involved in the financing and merger activity of over 20 medical device and healthcare technology companies. Mr. Barnes was a co-founder and CEO of Biosyss Corporation, a cardiovascular device company, and has held management positions in engineering, manufacturing and marketing within the Medical Products Group of Hewlett-Packard Corp. Mr. Barnes is a member of the Clinical Cardiology Council of the American Heart Association, the Association for the Advancement of Medical Instrumentation, and the National Society of Professional Engineers. In addition to serving on the Boards of Directors for many healthcare technology companies in the U.S., Europe, and Israel, he is a member of the Harvard-M.I.T. Health Sciences and Technology Advisory Council and the Board of Overseers of Newton-Wellesley Hospital in Newton, MA. He received a B.S. degree in Physiology & Biophysics, an M.S. degree in Engineering from Duke University and an M.S. degree from Stanford University Graduate School of Business.

Jack Davis is an experienced CEO with 25 years of general management experience in the healthcare industry. Jack was co-founder and CEO of DIANON Systems, a leading provider of specialized clinical laboratory and anatomic pathology testing services focused on cancer, prenatal genetics and cytogenetics. DIANON was taken public in 1991 and was sold to Laboratory Corp of America for $600MM in 2003. Jack had previously managed a $100MM worldwide diagnostic products business for Abbott Laboratories. He currently serves as Director of several med-tech companies. Jack holds a B.S. from Ohio State University, completed the Exec Development Program at Ohio State and served as an Adjunct Professor of Business at Sacred Heart University.

Marc Goldberg co-founded BioVentures Investors where he is a General Partner. He has over twenty years of experience in the biotechnology industry as both senior executive and deal maker. From 1991 to 1997 Mr. Goldberg was President and CEO of Massachusetts Biotechnology Research Institute (Worcester, Massachusetts). He was responsible for the financing, strategic direction, and operation of this private sector economic development organization which specialized in technology transfer and company formation. During his tenure, MBRI raised $20 million in funding and was responsible for the launch of 24 new biotechnology companies. MBRI's success served as a model for the development of similar systems throughout the U.S. as well as internationally. From 1987 to 1991, Mr. Goldberg held senior positions at Safer, Inc. (Newton, Massachusetts), including Chief Financial Officer and Vice President, Finance and Corporate Development. He negotiated four rounds of venture capital investment, numerous bank lines of credits, and multiple manufacturing contracts. He implemented all outside scientific collaborations with both public and private entities, handled the sale of Safer’s consumer division, managed the company between CEOs, positioned the company for sale, and negotiated the final merger agreement. Prior to Safer, Mr. Goldberg was Manager of Business Development at Genetics Institute, Inc. (Cambridge, Massachusetts) from 1983 to 1987. He was responsible for the company’s agricultural business development, strategic planning, and marketing functions. Mr. Goldberg co-founded the Massachusetts Biotechnology Council in 1985, and has served four terms as President and was a Director from its inception in 1985 until 1997. He has also served as a board member of numerous privately held companies. He was a member and principal author of the Governor’s Task Force, Subcommittee on Biotechnology and Pharmaceutical Development. He was a Governor of the Harvard Business School Association of Boston and was Chairman of the Board of Trustees at Worcester State College. Mr. Goldberg earned his A.B. from Harvard College (Phi Beta Kappa, magna cum laude), his J.D. from Harvard Law School (cum laude), and his M.B.A. from Harvard Business School.

Michael Lytton joined Oxford Bioscience Partners in January 2001, where he is a General Partner. Prior to that, he was Partner, Chairman of the Technology Group, and a member of the Executive Committee of Palmer & Dodge LLP, a Boston-based law firm. Mr. Lytton serves on the Boards of Directors of Alantos, Claros Diagnostics, Inc., Decision Biomarkers, Enanta, GPC Biotech, Radius, Rib-X, Santhera, and VaxInnate. Mr. Lytton was also responsible for investments by Oxford in Aveo and Concentric. Mr. Lytton is Chairman of the Research and Technology Committee of the Center for Blood Research, Harvard Medical School, where he is also a member of the Board of Trustees. Mr. Lytton also serves on the Board of Directors of the non-profit organization, Medicines in Need, a Harvard-based foundation sponsoring clinical development of a novel drug delivery technology to be used for medicines supplied to developing world countries. In addition, he serves on the Advisory Committee to Connecticut Innovations, a public agency funding early-stage biomedical companies in Connecticut. Mr. Lytton periodically contributes to a quarterly column on issues facing early-stage biomedical companies for Start-Up magazine, published by Windhover Information. Mr. Lytton has served on the Executive Board of the MIT Enterprise Forum and the Patent Committee of the Boston University Medical Center. He was a summa cum laude graduate of The Woodrow Wilson School of Public and International Affairs, Princeton University and a recipient of a Fulbright Scholarship for study at the University of London, and he received a J.D. degree cum laude from Harvard Law School. Mr. Lytton also received a M.Sc. degree in Epidemiology and Medical Statistics from the London School of Hygiene and Tropical Medicine.

Michael J. Magliochetti, Ph.D. was previously an Entrepreneur-in-Residence at Oxford Bioscience Partners. He was most recently CEO of RMH, a company focused in orthopedics, which was acquired. He was CEO of HemaMetrics, a private blood monitoring and diagnostic company. Dr. Magliochetti was CEO of UroSurge, specializing in products for the urology market of which a sale transaction was executed. He has held senior positions with the medical device company Haemonetics Corporation and the polymer products company Delta Surprenant. He currently serves on the Advisory Board for the Pediatric New Technology Initiatives Group of Boston Children's Hospital, the non-profit Institute for Pediatric Innovation, and has served as an Adjunct Professor of Biomedical Engineering at the University of Iowa. Dr. Magliochetti holds B.S. and Ph.D. degrees in Chemical Engineering from Northeastern University and the University of Massachusetts at Amherst, respectively, and a High Technology M.B.A. from Northeastern University.

Caroline Popper, M.D. is Founder and President of Popper & Co., a life sciences consulting firm. She has 17 years of biotech/life sciences operating experience managing businesses in diagnostics, devices and drug discovery in both Fortune 500 and start-up settings. Dr. Popper has extensive diagnostic industry experience with the majority of her career at Becton Dickinson, where her global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding GM of BDGene; a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. Dr. Popper has served as Chief Business Officer for MDS Proteomics, a multi-national drug discovery company. Dr. Popper received her MD from the University of the Witwatersrand (South Africa), completed her residencies in Internal Medicine and in Pathology at Johns Hopkins, and attained a MPH from Johns Hopkins University. She was also a Robert Wood Johnson Fellow in Health Care Finance.

David Steinmiller previously served as Director of Engineering at WebOligos and Eos Biotechnology where he developed instruments for genomics research. Mr. Steinmiller created and patented a high-throughput system for synthesizing nucleic acids and transitioned the technology from concept to prototype to production device. This technology formed the core of WebOligos, which produced and marketed synthetic DNA, and which was acquired by Invitrogen. Mr. Steinmiller holds a B.S. and M.S. in Mechanical Engineering from Stanford and an MBA from the MIT Sloan School of Management.